AstraZeneca is reportedly exploring a $400 billion merger with U.S.-based Bristol Myers Squibb, potentially forming one of the largest pharmaceutical companies in history.
The deal could be worth nearly $400 billion
Aug 03, 2026
12:30 pm
What's the storyBritish pharmaceutical giant AstraZeneca is said to be in talks with US rival Bristol Myers Squibb (BMS) for a possible merger.
The Financial Times reported that if the deal goes through, it would create one of the world's largest pharmaceutical companies with an estimated combined value of nearly $400 billion.
AstraZeneca in talks over £300bn mega-merger with US rival – reports
Astrazeneca explores $400bn megadeal with US rival
Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion megadeal: Report
UK's AstraZeneca eyeing $400b merger, report says
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)
AstraZeneca share prices drop amid £300bn mega-merger talks with US rival
$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
AstraZeneca said to have explored Bristol Myers merger | Fortune
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
AstraZeneca, Bristol Myers are in talks about merger — report
The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.
Astrazeneca is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb to create one of the world's largest pharma…
The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion. Read more…
The United Kingdom's second-most valuable listed company, pharmaceutical firm AstraZeneca, has been revealed to have been holding…
AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks ongoing for months, antitrust…
The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company
